Researchers Develop Nanozyme for Glioblastoma Treatment
A new antibody-functionalized nanoplatform shows promise in laboratory tests against glioblastoma cells.
Updated on Oct. 30, 2026 in Cancer
Live Poll
Should medical researchers prioritize rapid development of new cancer therapies over long-term safety testing?
In 2026, researchers published findings in the journal Polysaccharides detailing a new cobalt-substituted magnetite nanozyme designed to target glioblastoma. This immunoconjugate utilizes dual enzyodynamic-enabled ferroptosis and photothermal therapy to combat cancer cells.
Why it matters
The platform specifically targets CD44 receptors, which are highly expressed in aggressive glioblastoma and glioma stem-like cells. By enhancing precision in targeting these cells, the technology aims to improve the efficacy of localized cancer treatments.
The immunoconjugate exhibited an EC50 of 0.4 µg/mL in U-87 MG cells and maintained a hemolysis range of 2% to 5% at concentrations up to 20 µg/mL. Furthermore, the treatment reduced cell viability in 3D gliomaspheres to 34%.
The details
The immunoconjugate consists of 5.7 nm cobalt-substituted magnetite nanoparticles stabilized with carboxymethyl cellulose and functionalized with anti-CD44 antibodies. When combined with laser irradiation at 660 nm, the platform achieved 30% additional inhibition of glioma cells.
Timeline
The research findings were published in 2026.
The Big Picture
This development follows a pattern set by the ongoing development of nanozyme-based cancer therapies. The work extends the discipline by utilizing specific CD44-targeted antibody functionalization to enhance tumor cell selectivity.
The development represents an experimental milestone rather than an immediate clinical option for patients. Future applications could lead to new treatment modalities, but the technology must first clear significant safety and testing requirements.
The takeaway
This study demonstrates how functionalized nanoparticles can improve the precision of cancer cell targeting in a laboratory setting. Researchers remain focused on addressing the complexities of brain tissue delivery and long-term biocompatibility.
What happens next
Future research phases will involve in vivo preclinical testing to evaluate pharmacokinetics, safety profiles, and the ability of the nanoplatform to successfully traverse the blood-brain barrier.
Further reading
Learn more about emerging research in this field by visiting the Cancer section.
More information
Read the full study in the scientific paper in Polysaccharides journal.
Source note: This article includes information reported by AZoNano.
Live Poll
Should medical researchers prioritize rapid development of new cancer therapies over long-term safety testing?
